Skip to main content
Erschienen in: BMC Medical Imaging 1/2023

Open Access 01.12.2023 | Research

The value of preoperative positron emission tomography/computed tomography in differentiating the invasive degree of hypometabolic lung adenocarcinoma

verfasst von: Yuling Su, Hui Zhou, Wenshan Huang, Lei Li, Jinyu Wang

Erschienen in: BMC Medical Imaging | Ausgabe 1/2023

Abstract

Objectives

To investigate the value of preoperative positron emission tomography/computed tomography (PET/CT) in differentiating the invasive degree of hypometabolic lung adenocarcinoma.

Methods

We retrospectively analyzed the data of patients who underwent PET/CT examination, high-resolution computed tomography, and surgical resection for low-metabolism lung adenocarcinoma in our hospital between June 2016 and December 2021. We also investigated the relationship between the preoperative PET/CT findings and the pathological subtype of hypometabolic lung adenocarcinoma.

Results

A total of 128 lesions were found in 113 patients who underwent resection for lung adenocarcinoma, including 20 minimally invasive adenocarcinomas (MIA) and 108 invasive adenocarcinomas (IAC), whose preoperative PET/CT showed low metabolism. There were significant differences in the largest diameter (Dmax), lesion type, maximum standard uptake value (SUVmax), SUVindex (the ratio of SUVmax of lesion to SUVmax of contralateral normal lung paranchyma), fasting blood glucose, lobulation, spiculation, and pleura indentation between the MIA and IAC groups (p < 0.05). Multivariate logistic regression analysis showed that the Dmax (odds ratio (OR) = 1.413, 95% confidence interval (CI: 1.155–1.729, p = 0.001)) and SUVmax (OR = 12.137, 95% CI: 1.068–137.900, p = 0.044) were independent risk factors for predicting the hypometabolic IAC (p < 0.05). Receiver operating characteristic (ROC) curve analysis showed that the Dmax ≥ 10.5 mm and SUVmax ≥ 0.85 were the cut-off values for differentiating MIA from IAC, with high sensitivity (84.3% and 75.9%, respectively) and specificity (84.5% and 85.0%, respectively), the Combined Diagnosis showed higher sensitivity (91.7%) and specificity (85.0%).

Conclusions

The PET/CT findings correlated with the subtype of hypometabolic lung adenocarcinoma. The parameters Dmax and SUVmax were independent risk factors for predicting IAC, and the sensitivity of Combined Diagnosis prediction is better.
Hinweise

Supplementary Information

The online version contains supplementary material available at https://​doi.​org/​10.​1186/​s12880-023-00986-8.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Introduction

Lung cancer is one of the leading causes of cancer-related deaths globally [1]. In recent years, the incidence of lung cancer has risen yearly, becoming the most common malignant tumors, and adenocarcinoma has become the most common pathological type [2].
Lung cancer prognosis is closely related to tumor stage and pathological subtypes. Adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA) often present as ground glass nodules (GGNs) and are considered indolent forms of lung cancer [3, 4]. With radical resection, the disease-free 5-year survival rate of patients with MIA and AIS is approximately 100% [5]. Conversely, the prognosis of localized invasive adenocarcinoma (IAC) is relatively poor, and the 5-year survival rate is only 40–85% [4, 6]. Without treatment, the median survival time for patients with stage I lung cancer is ca. 13 months [7]. Thus, once early lung cancer is diagnosed, it should be treated quickly, and it is important to identify IAC as early as possible to increase the likelihood of a good outcome. However, it is almost impossible to obtain a pathological hypometabolic pulmonary lesion diagnosis without surgery.
Conventional imaging for the diagnosis of lung cancer are based on morphological changes and may not provide an early diagnosis. 18F-flurodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) reflects the proliferative activity and metabolic potential of tumor cells and is generally used for all aspects of lung cancer, such as diagnosis, preoperative staging, treatment efficacy evaluation, and prediction model construction [8, 9]. The maximum standard uptake value (SUVmax) is the most widely used semi-quantitative index for PET/CT. Generally, a SUVmax = 2.5 is used as the diagnostic threshold for differentiating benign and malignant tumors, and a SUVmax > 2.5 is regarded as malignant [10]. However, in practical clinical applications, some lung cancers show mild uptake of 18F-FDG or no obvious radioactive uptake.
There is limited information on the relationship between such hypometabolic lung cancers and the pathological subtype. Previous studies on hypometabolic lung cancer were mainly about lung adenocarcinoma featuring GGN [11, 12]. There have been no studies on simple hypometabolic lung cancer.
This study aimed to summarize the PET/CT imaging features of hypometabolic lung adenocarcinoma to find factors that could accurately predict the IAC preoperatively.

Materials and methods

Study design

All enrolled cases were lung adenocarcinoma diagnosed from June 2016 to December 2021 with preoperative PET/CT manifesting low metabolism. They also underwent a HRCT scan within 2 weeks of diagnosis. Pathological classification was based on the 2021 World Health Organization (WHO) classification of thoracic tumors.
Patient information, including age, gender, fasting blood glucose, height, weight, imaging features, quantitative parameters of PET/CT and HRCT, and postoperative pathological results were recorded. This study was approved by the Institutional Review Board of Zhuhai People’s Hospital in Guangdong Province, China. The requirement for informed consent was waived due to the retrospective nature of the study design.

Inclusion and exclusion criteria

Inclusion criteria were as follows: (I) all lesions were surgically resected and confirmed to be MIA or IAC by pathological examination; (II) PET/CT and thoracic HRCT were conducted before the operation, and the SUVmax of the lesion was < 2.5; (III) all lesions were surgically resected, and the pathological results was integrity, and the final pathology certified MIA or IAC; and (IV) patients had no history of malignant tumors or diabetes. Exclusion criteria were as follows: (I) poor image quality or undistinguished lesion boundary; or (II) the patient had previous anti-tumor therapy.

Imaging equipment and methods

The Philips Gemini TF PET/CT scanner (Philips Medical Systems, Best, The Netherlands) was applied to conduct the 18F-FDG PET/CT imaging. The radiolabel was 18F-FDG (Atom High-tech Isotope Pharmaceutical Co., Ltd., Guangzhou, China; radiochemical purity > 95%). Patients were fasted for more than 4 h before examination. Fasting blood glucose was measured before intravenous injection of 18F-FDG (4.07–5.18 MBq/kg). Patients were allowed to rest for 60 min in a quiet, warm, dark condition before PET/CT examination.
The CT machine was fitted with a tube voltage of 80 kV, a tube current of 150 mAs, a screw pitch of 0.8, a rotation time of 0.5 s, and a layer thickness of 2 mm. PET acquisition was performed in three-dimensional mode; the scope of acquisition was from the upper thigh to the cranial roof, and the scanning time was 70 s/bed. The EBW system (Philips, Netherlands) was used for image reading.
HRCT acquisition was conducted while the patient was holding breath, and the scope of the scan was the lung lesion only. The acquisition parameters were as follows: (1) 120 kV, (2) 250 mAs, (3) pitch 0.8, and (4) slice thickness 1.0 mm. The lung window width and window level were 1,200 (Hounsfield unit) HU and − 600 HU, and the mediastinal window width and level were 350 HU and 40 HU, respectively.

Image analysis

Two experienced nuclear physicians with more than 8 years of experience who were blinded to the pathology and clinical data, read all the lesions on the HRCT images. When they had a dispute, they consulted a third senior physician.
The PET quantitative indicators included SUVmax (SUVmax of the lung lesion), *SUVmax (SUVmax of normal lung parenchyma), and SUVindex (the ratio of SUVmax to *SUVmax). The SUVmax was obtained on the PET/CT fusion image of the lung window. We constructed a region of interest (ROI) that covered the lung lesion integrally, and the SUVmax were measured in all layers. SUVmax was measured at the same position in the contralateral lung lobe using the same size ROI.
In lung CT images, a ground-glass nodule (GGN) lesion is defined as a hazy increase in attenuation in the lung with preservation of intact bronchial and vascular structures [13]. GGNs are further divided into pure GGNs (pGGNs) and mixed GGNs (mGGNs) [14]. The types of lesions were determined according to the ground-glass component of the lesions, including pGGNs, mGGNs, and solid lesions.
The HRCT parameters of the lung lesions were including: Dmax (maximal diameter), lesion type (pGGN, mGGN, or solid lesion), lobulation, spiculation, vessel relationship (vessel penetrating the lesion or no), and pleural retraction.

Statistical analysis

GraphPad Prism (Version 9.2), MedCalc (Version 19.0), and SPSS (Version 25.0, IBM) were used for data analysis. Normally distributed data were expressed as mean ± standard deviation, and nonnormal data were expressed as the median (interquartile range). Comparisons between two groups of normally distributed data were analyzed using a Student’s t-tests, and comparisons between two groups of nonnormal data were analyzed using the Mann–Whitney U test. The qualitative data were expressed as frequency (percentages). Chi-squared test were used for qualitative data.
The parameters with a p-value < 0.05 were finally included in the multivariate logistic regression (forward stepwise) equation. We first constructed the receiver operating characteristic (ROC) curve of Dmax, SUVmax, and the Combined, then used the Youden index (sensitivity + specificity-1) to determine their cut-off values to predict IAC, and finally calculated the area under the curve (AUC). A p-value < 0.05 was considered statistically significant.

Results

In total, 128 lesions in 113 patients (48 men and 65 women) aged 30–81 years were analyzed in the present study. Twenty lesions were diagnosed as MIA, and 108 were diagnosed as IAC (Fig. 1). The Dmax of the lesion was 4–47 mm. All patients were free of lymph nodes and distant metastases.

Comparison between MIA and IAC

Our study showed that there were significant differences in age, Dmax, SUVmax, SUVindex and fasting blood glucose between the MIA and the IAC group (all p < 0.05). Significant differences in terms of lesion type, the incidence of lobulation, the incidence of spiculation, and the incidence of pleural retraction were also observed between the two groups (all p < 0.05). In our study, pGGNs were more common in MIA (16/20), while mGGNs were more common in IAC (62/108), and solid lesions only existed in IAC (Table 1).
Table 1
Characteristics between MIA and IAC groups
 
MIA(n = 20)
IAC(n = 108)
P-value
Age (years)
54.7 ± 12.28
61.44 ± 10.49
0.011a
Dmax (mm)
7.5 [6.0, 9.75]
16 [13, 21]
< 0.001c
SUVmax
0.6 [0.5, 0.8]
1.2 [0.9, 1.6]
< 0.001c
SUVindex
1.0 [1.0, 1.0]
1.0 [1.3, 2.3]
< 0.001c
Fasting blood glucose
5.4 [5.3, 5.85]
5.8 [5.42, 6.5]
0.032b
Height
162.55 ± 6.684
160.58 ± 6.965
0.245a
Weight
63.53 ± 10.203
60.17 ± 9.085
0.139a
Gender ratio
Male
10(50.0%)
44(40.7%)
0.441b
Female
10(50.0%)
64(59.3%)
 
Lesion type [n(%)]
Pure GGN
16(80.0%)
34(31.5%)
< 0.001b
Mixed GGN
4(20.0%)
62(57.4%)
 
Solid
0(0.0%)
12(11.1%)
 
Lobulation n[(%)]
Yes
3(5.4%)
53(94.6%)
0.005b
No,
17(23.6%)
55(76.4%)
 
Spiculation n[(%)]
Yes
1(2.3%)
43(97.7%)
0.003b
No
19(22.6%)
65(77.4%)
 
Vessel relationship n[(%)]
Yes
5(11.1%)
40(88.9%)
0.406b
No
15(18.1%)
68(81.9%)
 
Plearal retraction n[(%)]
Yes
5(6.8%)
68(93.2%)
0.002b
No
15(27.3%)
40(72.7%)
 
aStatistical analysis performed using independent-samples T test
bStatistical analysis performed using chi-square test
cStatistical analysis performed using Mann–Whitney U test

Binary logistic regression analysis and AUC

The statistically significant variables in Table 1 were used to perform binary logistic regression analysis. In the binary logistic regression analysis, IAC was included as the dependent variable, age, Dmax, SUVmax, SUVindex, fasting blood glucose, lesion type, lobulation, spiculation, and vessel relationship were considered covariates. After excluding non-statistically significant independent variables, we found that only Dmax (OR = 1.413, 95% CI: 1.155–1.729, p = 0.001) and SUVmax (OR = 12.137, 95% CI: 1.068–137.900, p = 0.044) were independent risk factors for predicting IAC (Table 2).
Table 2
Logistic regression analysis for the Dmax and SUVmax
 
B
S.E.
Wald
df
Sig.
Exp(B)
95% CI for EXP(B)
Lower
Upper
Variables in the equation
Dmax
0.345
0.103
11.308
1
0.001
1.413
1.155
1.729
SUVmax
2.489
1.239
4.035
1
0.044
12.137
1.068
137.900
Constant
− 4.606
1.203
14.666
1
0.000
0.01
  
S.E. standard error; df free degree; Sig significance; CI confidence interval
The ROC curve analysis of Dmax, SUVmax, and the Combined Diagnosis showed that the AUC value was 0.913, 0.857, and 0.928, respectively. The sensitivity was 84.3% and the specificity was 84.5% when the Dmax was ≥ 10.5 mm in predicting IAC. Similarly, the sensitivity was 75.9% and the specificity was 85.0% when the SUVmax ≥ 0.85. The Combined Diagnosis showed higher sensitivity (91.7%) and specificity (85.0%) (Table 3). But, only the AUC difference between the Combined Diagnosis and SUVmax was statistically significant (Fig. 2A–C).
Table 3
Receiver operating characteristic curves parameters for predicting IAC
AUC (95% CI)
Cut-off
Se (%)
Sp (%)
P
Dmax
0.913 (0.852–0.974)
10.5
84.3
84.5
< 0.001
SUVmax
0.857 (0.764–0.950)
0.85
75.9
85.0
< 0.001
Combined diagnosis
0.928 (0.869–0.986)
0.7371
91.7
85.0
< 0.001
IAC invasive adenocarcinoma, AUC area under the curve, CI confidence interval, Se Sensitivity, Sp Specificity

Discussion

The present study showed that the PET/CT parameters using SUVmax and Dmax were better than other indicators for differentiating hypometabolic IAC from MIA. Concurrently, ROC curve analysis showed that Dmax ≥ 10.5 mm and SUVmax ≥ 0.85 were used as the cut-off values to differentiate MIA from IAC, which had high sensitivity and specificity, and the sensitivity of the Combined Prediction is better.
Previous studies [1517] involving low-metabolic lung cancer were GGN, with the authors arguing that the SUVmax of GGN was independently associated with the risk of early lung adenocarcinoma invasion and had a linear positive correlation. Other studies demonstrated that the SUVmax in 18F-FDG PET correlates with the pathologic type and degree of differentiation of lung cancer and is an indicator of the proliferative ability of lung cancer cells [18, 19].
Unlike previous studies, the cases in our study included pGGNs, mGGNs, and solid lesions. The SUVmax of all lung lesions was < 2.5 and the SUVmax of pulmonary background ranged from 0.4 to 1.3, with no lymph nodes or distant metastases.
Our research found that the SUVmax of IAC was statistically significantly higher than the SUVmax of MIA, which was consistent with some previous studies. The level of lung cancer glucose metabolism is correlated with a variety of factors, such as glycolysis-related gene expression, tumor immune microenvironment, Ki-67 expression, epidermal growth factor receptor, and tumor protein 53 mutation, among others [2022]. Elevated SUVmax in lung cancer often indicates a higher possibility of malignant lesions or poor prognosis [23]. This further indicates low-grade malignancy and a good prognosis of hypometabolic lung cancer.
The SUVmax of IAC is higher than MIA [11]. However, the SUVmax may be affected by multiple factors, such as blood glucose, body weight, and the PET/CT algorithm. Ohba et al. [24] has used the contralateral lung as a control to calculate SUVindex and confirmed appropriate in the evaluation of well-differentiated lung cancer.
Our study found that the SUVindex in IAC was significantly higher than in MIA. However, it was not found as independent predictor in the logistic regression analysis. This may be due to the included cases were different. In our study, half of the lesions did not show radioactive uptake, the diagnostic roles of CT were better than PET for those cases, which ultimately affected the diagnostic performance of ROC curve.
At the same time, our study also found that there was no significant correlation between Fasting blood glucose, Height, Weight, Age, Gender, and SUVmax (Additional file 1).
With the increase of the nodule diameter, the SUVmax would be higher [25]. Based on clinical data, nodule size is an independent predictive factor for lung cancer, as increases in lung nodule size increases the likelihood of malignancy [26]. This study further investigated the difference in Dmax between MIA and IAC groups with low metabolism, and the results showed that the Dmax of IAC was statistically significantly larger than the Dmax of MIA. The same is true of the difference in SUVmax between IAC and MIA groups.
Liu et al. [27]. Analyzed the CT images of 172 patients and obtained the best four features to predict the malignant status of the lesions, including lobulation and burr sign. However, some studies suggested that there was no statistically significant difference between lobulation and pleural pull sign in the identification of invasiveness [28, 29]. Our study found that the IAC risk increased with an increase in lobulation, spiculation, and pleural depression. However, these signs were not found as independent predictors in the logistic regression analysis. This may be due to the low percentage of MIA (20/128 lesions).
The present study had some limitations. First, this study is a retrospective study, and there may be a selection bias in the collection of cases. Second, due to the short follow-up period of patients enrolled in this study, and the good prognosis of low-metabolic lung cancer, there was no recurrence and death at present, the influence of preoperative SUVmax on predicting postoperative prognosis and survival was not analyzed in this study. Third, this study contains only patients with adenocarcinoma. Some benign lung lesions may also have similar features. We will concentrate this in our upcoming study.
In conclusion, the present study showed that 18F-FDG PET/CT played an important role in differentiating the invasive degree of hypometabolic lung adenocarcinoma, the parameters Dmax and SUVmax could be used as independent risk factors to predict the hypometabolic IAC, and the sensitivity of the diagnosis was better when using both indicators simultaneously.

Acknowledgements

Thanks to the colleagues who provided help in this study.

Declarations

(1) All methods of the study were carried out in accordance with relevant guidelines and regulations. (2) All experimental protocols were approved and consented by the Ethics Committee of Zhuhai People’s Hospital. (3) The need for written informed consent was waived by the Ethics Committee of Zhuhai People’s Hospital due to retrospective nature of the study.
Not applicable.

Competing interests

The authors have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
2.
Zurück zum Zitat Hsu WH, Yang JC, Mok TS, Loong HH. Overview of current systemic management of EGFR-mutant NSCLC. Ann Oncol. 2018;29(suppl 1):i3–9.CrossRefPubMed Hsu WH, Yang JC, Mok TS, Loong HH. Overview of current systemic management of EGFR-mutant NSCLC. Ann Oncol. 2018;29(suppl 1):i3–9.CrossRefPubMed
3.
Zurück zum Zitat Qiu ZX, Cheng Y, Liu D, Wang WY, Wu X, Wu WL, et al. Clinical, pathological, and radiological characteristics of solitary ground-glass opacity lung nodules on high-resolution computed tomography. Ther Clin Risk Manag. 2016;12:1445–53.CrossRefPubMedPubMedCentral Qiu ZX, Cheng Y, Liu D, Wang WY, Wu X, Wu WL, et al. Clinical, pathological, and radiological characteristics of solitary ground-glass opacity lung nodules on high-resolution computed tomography. Ther Clin Risk Manag. 2016;12:1445–53.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Nakamura H, Saji H, Shinmyo T, Tagaya R, Kurimoto N, Koizumi H, et al. Close association of IASLC/ATS/ERS lung adenocarcinoma subtypes with glucose-uptake in positron emission tomography. Lung Cancer. 2015;87(1):28–33.CrossRefPubMed Nakamura H, Saji H, Shinmyo T, Tagaya R, Kurimoto N, Koizumi H, et al. Close association of IASLC/ATS/ERS lung adenocarcinoma subtypes with glucose-uptake in positron emission tomography. Lung Cancer. 2015;87(1):28–33.CrossRefPubMed
5.
Zurück zum Zitat Boland JM, Froemming AT, Wampfler JA, Maldonado F, Peikert T, Hyland C, et al. Adenocarcinoma in situ, minimally invasive adenocarcinoma, and invasive pulmonary adenocarcinoma–analysis of interobserver agreement, survival, radiographic characteristics, and gross pathology in 296 nodules. Hum Pathol. 2016;51:41–50.CrossRefPubMed Boland JM, Froemming AT, Wampfler JA, Maldonado F, Peikert T, Hyland C, et al. Adenocarcinoma in situ, minimally invasive adenocarcinoma, and invasive pulmonary adenocarcinoma–analysis of interobserver agreement, survival, radiographic characteristics, and gross pathology in 296 nodules. Hum Pathol. 2016;51:41–50.CrossRefPubMed
6.
Zurück zum Zitat Gong J, Liu J, Hao W, Nie S, Zheng B, Wang S, et al. A deep residual learning network for predicting lung adenocarcinoma manifesting as ground-glass nodule on CT images. Eur Radiol. 2020;30(4):1847–55.CrossRefPubMed Gong J, Liu J, Hao W, Nie S, Zheng B, Wang S, et al. A deep residual learning network for predicting lung adenocarcinoma manifesting as ground-glass nodule on CT images. Eur Radiol. 2020;30(4):1847–55.CrossRefPubMed
7.
Zurück zum Zitat Raz DJ, Zell JA, Ou SH, Gandara DR, Anton-Culver H, Jablons DM. Natural history of stage I non-small cell lung cancer: implications for early detection. Chest. 2007;132(1):193–9.CrossRefPubMed Raz DJ, Zell JA, Ou SH, Gandara DR, Anton-Culver H, Jablons DM. Natural history of stage I non-small cell lung cancer: implications for early detection. Chest. 2007;132(1):193–9.CrossRefPubMed
8.
Zurück zum Zitat Wang Y, Zhao N, Wu Z, Pan N, Shen X, Liu T, et al. New insight on the correlation of metabolic status on 18F-FDG PET/CT with immune marker expression in patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2020;47(5):1127–36.CrossRefPubMed Wang Y, Zhao N, Wu Z, Pan N, Shen X, Liu T, et al. New insight on the correlation of metabolic status on 18F-FDG PET/CT with immune marker expression in patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2020;47(5):1127–36.CrossRefPubMed
9.
Zurück zum Zitat Kawakita N, Toba H, Kawakami Y, Takizawa H, Bando Y, Otuska H, et al. Use of a prognostic risk score that aggregates the FDG-PET/CT SUVmax, tumor size, and histologic group for predicting the prognosis of pStage I lung adenocarcinoma. Int J Clin Oncol. 2020;25(6):1079–89.CrossRefPubMed Kawakita N, Toba H, Kawakami Y, Takizawa H, Bando Y, Otuska H, et al. Use of a prognostic risk score that aggregates the FDG-PET/CT SUVmax, tumor size, and histologic group for predicting the prognosis of pStage I lung adenocarcinoma. Int J Clin Oncol. 2020;25(6):1079–89.CrossRefPubMed
10.
Zurück zum Zitat Acker MR, Burrell SC. Utility of 18F-FDG PET in evaluating cancers of lung. J Nucl Med Technol. 2005;33(2):69–74.PubMed Acker MR, Burrell SC. Utility of 18F-FDG PET in evaluating cancers of lung. J Nucl Med Technol. 2005;33(2):69–74.PubMed
11.
Zurück zum Zitat Son BY, Cho S, Yum SW, Kim K, Jheon S. The maximum standardized uptake value of preoperative positron emission tomography/computed tomography in lung adenocarcinoma with a ground-glass opacity component of less than 30 mm. J Surg Oncol. 2018;117(3):451–6.CrossRefPubMed Son BY, Cho S, Yum SW, Kim K, Jheon S. The maximum standardized uptake value of preoperative positron emission tomography/computed tomography in lung adenocarcinoma with a ground-glass opacity component of less than 30 mm. J Surg Oncol. 2018;117(3):451–6.CrossRefPubMed
12.
Zurück zum Zitat Niu R, Shao X, Shao X, Wang J, Jiang Z, Wang Y. Lung adenocarcinoma manifesting as ground-glass opacity nodules 3 cm or smaller: evaluation with combined high-resolution CT and PET/CT modality. AJR Am J Roentgenol. 2019;213(5):W236–45.CrossRefPubMed Niu R, Shao X, Shao X, Wang J, Jiang Z, Wang Y. Lung adenocarcinoma manifesting as ground-glass opacity nodules 3 cm or smaller: evaluation with combined high-resolution CT and PET/CT modality. AJR Am J Roentgenol. 2019;213(5):W236–45.CrossRefPubMed
13.
Zurück zum Zitat Kim HY, Shim YM, Lee KS, Han J, Yi CA, Kim YK. Persistent pulmonary nodular ground-glass opacity at thin-section CT: histopathologic comparisons. Radiology. 2007;245(1):267–75.CrossRefPubMed Kim HY, Shim YM, Lee KS, Han J, Yi CA, Kim YK. Persistent pulmonary nodular ground-glass opacity at thin-section CT: histopathologic comparisons. Radiology. 2007;245(1):267–75.CrossRefPubMed
14.
Zurück zum Zitat Hansell DM, Bankier AA, MacMahon H, McLoud TC, Müller NL, Remy J. Fleischner society: glossary of terms for thoracic imaging. Radiology. 2008;246(3):697–722.CrossRefPubMed Hansell DM, Bankier AA, MacMahon H, McLoud TC, Müller NL, Remy J. Fleischner society: glossary of terms for thoracic imaging. Radiology. 2008;246(3):697–722.CrossRefPubMed
15.
Zurück zum Zitat Qi L, Lu W, Yang L, Tang W, Zhao S, Huang Y, et al. Qualitative and quantitative imaging features of pulmonary subsolid nodules: differentiating invasive adenocarcinoma from minimally invasive adenocarcinoma and preinvasive lesions. J Thorac Dis. 2019;11(11):4835–46.CrossRefPubMedPubMedCentral Qi L, Lu W, Yang L, Tang W, Zhao S, Huang Y, et al. Qualitative and quantitative imaging features of pulmonary subsolid nodules: differentiating invasive adenocarcinoma from minimally invasive adenocarcinoma and preinvasive lesions. J Thorac Dis. 2019;11(11):4835–46.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Zhu Y, Hou D, Lan M, Sun X, Ma X. A comparison of ultra-high-resolution CT target scan versus conventional CT target reconstruction in the evaluation of ground-glass-nodule-like lung adenocarcinoma. Quant Imaging Med Surg. 2019;9(6):1087–94.CrossRefPubMedPubMedCentral Zhu Y, Hou D, Lan M, Sun X, Ma X. A comparison of ultra-high-resolution CT target scan versus conventional CT target reconstruction in the evaluation of ground-glass-nodule-like lung adenocarcinoma. Quant Imaging Med Surg. 2019;9(6):1087–94.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Shao X, Shao X, Niu R, Jiang Z, Xu M, Wang Y. Investigating the association between ground-glass nodules glucose metabolism and the invasive growth pattern of early lung adenocarcinoma. Quant Imaging Med Surg. 2021;11(8):3506–17.CrossRefPubMedPubMedCentral Shao X, Shao X, Niu R, Jiang Z, Xu M, Wang Y. Investigating the association between ground-glass nodules glucose metabolism and the invasive growth pattern of early lung adenocarcinoma. Quant Imaging Med Surg. 2021;11(8):3506–17.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Suzawa N, Ito M, Qiao S, Uchida K, Takao M, Yamada T, et al. Assessment of factors influencing FDG uptake in non-small cell lung cancer on PET/CT by investigating histological differences in expression of glucose transporters 1 and 3 and tumour size. Lung Cancer. 2011;72(2):191–8.CrossRefPubMed Suzawa N, Ito M, Qiao S, Uchida K, Takao M, Yamada T, et al. Assessment of factors influencing FDG uptake in non-small cell lung cancer on PET/CT by investigating histological differences in expression of glucose transporters 1 and 3 and tumour size. Lung Cancer. 2011;72(2):191–8.CrossRefPubMed
19.
Zurück zum Zitat Sun XY, Chen TX, Chang C, Teng HH, Xie C, Ruan MM, et al. SUVmax of 18FDG PET/CT predicts histological grade of lung adenocarcinoma. Acad Radiol. 2021;28(1):49–57.CrossRefPubMed Sun XY, Chen TX, Chang C, Teng HH, Xie C, Ruan MM, et al. SUVmax of 18FDG PET/CT predicts histological grade of lung adenocarcinoma. Acad Radiol. 2021;28(1):49–57.CrossRefPubMed
20.
Zurück zum Zitat Mitchell KG, Amini B, Wang Y, Carter BW, Godoy MCB, Parra ER, et al. 18F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer. Cancer Immunol Immunother. 2020;69(8):1519–34.CrossRefPubMedPubMedCentral Mitchell KG, Amini B, Wang Y, Carter BW, Godoy MCB, Parra ER, et al. 18F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer. Cancer Immunol Immunother. 2020;69(8):1519–34.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Watanabe K, Nomori H, Ohtsuka T, Naruke T, Ebihara A, Orikasa H, et al. [F-18]Fluorodeoxyglucose positron emission tomography can predict pathological tumor stage and proliferative activity determined by Ki-67 in clinical stage IA lung adenocarcinomas. Jpn J Clin Oncol. 2006;36(7):403–9.CrossRefPubMed Watanabe K, Nomori H, Ohtsuka T, Naruke T, Ebihara A, Orikasa H, et al. [F-18]Fluorodeoxyglucose positron emission tomography can predict pathological tumor stage and proliferative activity determined by Ki-67 in clinical stage IA lung adenocarcinomas. Jpn J Clin Oncol. 2006;36(7):403–9.CrossRefPubMed
22.
Zurück zum Zitat Li Y, Li X, Li H, Zhao Y, Liu Z, Sun K, et al. Genomic characterisation of pulmonary subsolid nodules: mutational landscape and radiological features. Eur Respir J. 2020;55(2):1901409.CrossRefPubMed Li Y, Li X, Li H, Zhao Y, Liu Z, Sun K, et al. Genomic characterisation of pulmonary subsolid nodules: mutational landscape and radiological features. Eur Respir J. 2020;55(2):1901409.CrossRefPubMed
23.
Zurück zum Zitat Lee HY, Lee SW, Lee KS, Jeong JY, Choi JY, Kwon OJ, et al. Role of CT and PET imaging in predicting tumor recurrence and survival in patients with lung adenocarcinoma: a comparison with the international association for the study of lung cancer/American thoracic society/European respiratory society classification of lung adenocarcinoma. J Thorac Oncol. 2015;10(12):1785–94.CrossRefPubMed Lee HY, Lee SW, Lee KS, Jeong JY, Choi JY, Kwon OJ, et al. Role of CT and PET imaging in predicting tumor recurrence and survival in patients with lung adenocarcinoma: a comparison with the international association for the study of lung cancer/American thoracic society/European respiratory society classification of lung adenocarcinoma. J Thorac Oncol. 2015;10(12):1785–94.CrossRefPubMed
24.
Zurück zum Zitat Ohba Y, Nomori H, Shibata H, Kobayashi H, Mori T, Shiraishi S, et al. Evaluation of semiquantitative assessments of fluorodeoxyglucose uptake on positron emission tomography scans for the diagnosis of pulmonary malignancies 1 to 3 cm in size. Ann Thorac Surg. 2009;87(3):886–91.CrossRefPubMed Ohba Y, Nomori H, Shibata H, Kobayashi H, Mori T, Shiraishi S, et al. Evaluation of semiquantitative assessments of fluorodeoxyglucose uptake on positron emission tomography scans for the diagnosis of pulmonary malignancies 1 to 3 cm in size. Ann Thorac Surg. 2009;87(3):886–91.CrossRefPubMed
25.
Zurück zum Zitat Shao X, Niu R, Jiang Z, Shao X, Wang Y. Role of PET/CT in management of early lung adenocarcinoma. AJR Am J Roentgenol. 2020;214(2):437–45.CrossRefPubMed Shao X, Niu R, Jiang Z, Shao X, Wang Y. Role of PET/CT in management of early lung adenocarcinoma. AJR Am J Roentgenol. 2020;214(2):437–45.CrossRefPubMed
26.
Zurück zum Zitat Henschke CI, Yankelevitz DF, Naidich DP, McCauley DI, McGuinness G, Libby DM, et al. CT screening for lung cancer: suspiciousness of nodules according to size on baseline scans. Radiology. 2004;231(1):164–8.CrossRefPubMed Henschke CI, Yankelevitz DF, Naidich DP, McCauley DI, McGuinness G, Libby DM, et al. CT screening for lung cancer: suspiciousness of nodules according to size on baseline scans. Radiology. 2004;231(1):164–8.CrossRefPubMed
27.
Zurück zum Zitat Liu Y, Balagurunathan Y, Atwater T, Antic S, Li Q, Walker RC, et al. Radiological image traits predictive of cancer status in pulmonary nodules. Clin Cancer Res. 2017;23(6):1442–9.CrossRefPubMed Liu Y, Balagurunathan Y, Atwater T, Antic S, Li Q, Walker RC, et al. Radiological image traits predictive of cancer status in pulmonary nodules. Clin Cancer Res. 2017;23(6):1442–9.CrossRefPubMed
28.
Zurück zum Zitat Liu LH, Liu M, Wei R, Jin EH, Liu YH, Xu L, et al. CT findings of persistent pure ground glass opacity: can we predict the invasiveness? Asian Pac J Cancer Prev. 2015;16(5):1925–8.CrossRefPubMed Liu LH, Liu M, Wei R, Jin EH, Liu YH, Xu L, et al. CT findings of persistent pure ground glass opacity: can we predict the invasiveness? Asian Pac J Cancer Prev. 2015;16(5):1925–8.CrossRefPubMed
29.
Metadaten
Titel
The value of preoperative positron emission tomography/computed tomography in differentiating the invasive degree of hypometabolic lung adenocarcinoma
verfasst von
Yuling Su
Hui Zhou
Wenshan Huang
Lei Li
Jinyu Wang
Publikationsdatum
01.12.2023
Verlag
BioMed Central
Erschienen in
BMC Medical Imaging / Ausgabe 1/2023
Elektronische ISSN: 1471-2342
DOI
https://doi.org/10.1186/s12880-023-00986-8

Weitere Artikel der Ausgabe 1/2023

BMC Medical Imaging 1/2023 Zur Ausgabe

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.